Toll free: 1-855 542-5672 (1-855-KICK-MSA)

Alterity Therapeutics Update on ATH434 – July 1, 2021

Published by defeatmsa

June 30, 2021

Defeat MSA Alliance Board of Directors is pleased to report some good news from Alterity Therapeutics on ATH434, a new drug being developed by the company for the treatment of Multiple System Atrophy.


Alterity is on track to launch the Phase 2 trial of its lead clinical candidate ATH434 by the end of the calendar year. ATH434 is a small molecule drug being developed for Multiple System Atrophy (MSA), a form of atypical parkinsonism where iron plays a key role in pathogenesis by promoting α-synuclein aggregation. The scientific investigation of ATH434, along with the results from the Phase 2 study, will augment the development and optimization of novel compounds expected to emerge from the new patent.”

For the full report from Alterity, visit their press release here

You May Also Like…

1 Comment

  1. Judy Zimpel

    This adds to our Hope


Submit a Comment

Your email address will not be published. Required fields are marked *

Copy link
Powered by Social Snap